AER 001
Phase 2Small molecule
AER 001 is one of 37 small molecule programs targeting Atopic Asthma. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Cinqair
TevaPreclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Atrovent
Boehringer IngelheimPreclinical
Symbicort
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Aciphex
Akero TherapeuticsPreclinical
AER 001
AAerovance, Inc.
Phase 2
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Tylenol
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Atopic Asthma2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AER 001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAerovance, Inc.